Jubilant Ingrevia Limited announced the acquisition of 100% equity stake in Remidex Pharma Private Limited for a Cash Consideration of Rs. 16.5 crore. The transaction, which closes within 30 days, aims to strategically move the company up the value chain into Premixes for Human Nutrition. Remidex, specializing in micronutrient premixes and nutraceuticals, had a turnover of Rs. 24.27 Cr. in FY 24-25.
Strategic Acquisition of Remidex Pharma
Jubilant Ingrevia Limited has entered into a definitive Share Purchase Agreement to acquire 100% of the equity shareholding in Remidex Pharma Private Limited. Following the successful acquisition, Remidex will become a wholly owned subsidiary of Jubilant Ingrevia.
Financial Terms and Timing
The Cost of acquisition is set at Rs. 16.5 crore, subject to customary closing conditions. The consideration will be paid entirely as a Cash Consideration. The indicative time period set for the completion of the acquisition is 30 days from the date of this announcement, which occurred on March 13, 2026.
Target Entity Profile (Remidex)
Remidex Pharma Private Limited was incorporated in June 1981. It operates in the Human Nutrition – Premix and Pharmaceutical manufacturing industry, specializing in manufacturing and selling micronutrient premixes and nutraceuticals. It also functions as a contract manufacturing organization for pharmaceutical companies.
Key Historical Turnover Data:
- FY 24-25: Rs. 24.27 Cr.
- FY 23-24: Rs. 31.15 Cr.
- FY 22-23: Rs. 30.51 Cr.
Rationale and Business Impact
This acquisition is a key strategic move designed to enable Jubilant Ingrevia to progress in the value chain, specifically targeting the Premixes in Human Nutrition Space. This move is expected to build upon the company’s existing leadership position in the Vitamins segment, particularly in Vitamin B3 & B4 manufacturing.
Regulatory Compliance
The acquisition does not fall within the scope of related party transactions. Furthermore, no specific governmental or regulatory approvals are currently noted as required for the transaction to proceed.
Source: BSE
